# **Special Issue**

# **Emerging Trends in Thyroid Cancer**

## Message from the Guest Editor

Thyroid cancer is the most frequent malignancy of the endocrine system. In recent decades, the incidence of thyroid cancer has been growing at a shocking rate, which has aroused increasing concerns worldwide. Therefore, looking for new therapeutic strategies is of great importance for thyroid cancers. In this Special Issue, we welcome original studies on the diagnosis, pathophysiology and therapy of thyroid cancer. We particularly welcome contributions on all aspects related to providing novel mechanistic insights into the underlying pathogenesis or new aspects that may impact clinical therapy, and recent study results in order to review the current status of new therapy options in thyroid cancer.

#### **Guest Editor**

Dr. Rodis D. Paparodis

- 1. Hellenic Endocrine Network, 105 63 Athens, Greece
- 2. Loyola University Medical Center, Maywood, IL 60153, USA
- 3. Edward Hines Jr. VA Hospital, Hines, IL 60141, USA

# Deadline for manuscript submissions

closed (30 June 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/191855

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





# **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).